


Product Name : AMXI-5001
Cat. No. : PC-72149
CAS No. : 2170491-77-5
Molecular Formula : C₂₅H₂₀FN₅O₃
Molecular Weight : 457.465
Target : PARP
Solubility : 10 mM in DMSO



Biological Activity

AMXI-5001 (AMXI 5001) is a novel, highly potent, orally active dual **PARP1/2** (IC₅₀ 5/0.05 nM) and microtubule polymerization inhibitor, inhibits intracellular PAR formation with IC₅₀ of 7 nM.

AMXI-5001 binds to the catalytic domain of human PARP1 and is a weak tankyrase inhibitor (800-fold lower than IC₅₀ towards either PARP1 or PARP2 enzymes).

AMXI-5001 inhibited tubulin polymerization in a dose-dependent manner.

AMXI-5001 exhibited selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors.

AMXI-5001 is highly active in both BRCA mutated and wild type cancers.

AMXI-5001 elicited a remarkable In vivo preclinical anti-tumor activity in a BRCA mutated TNBC model induced complete regression of established tumors, including exceedingly large tumors, demonstrated superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents.

References

Hassan Lemjabbar-Alaoui, et al. *Am J Cancer Res.* 2020 Aug 1;10(8):2649-2676.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com